Joint Statement on an Inclusive Pharmaceutical Strategy

For the first time, in known history, EU policy recommendations were made featuring psychedelic-assisted psychotherapy.

”New models of innovative/unusual treatments when they target unmet needs or vulnerable situations, for instance, psychedelic assisted therapies for brain disorders, which constitute a paradigm shift in the pharmacological space because these therapies will need to be registered as both a medicinal product and therapy.”